U.S. FDA approves Jazz Pharma's drug for excessive daytime sleepiness
Aug 12 (Reuters) - Jazz Pharmaceuticals PLC said on Thursday the U.S. Food and Drug Administration has approved its sleep disorder drug Xywav for expanded use in patients suffering from excessive daytime sleepiness despite a good night's sleep.
Xywav is currently approved in the United States for the treatment of excessive daytime sleepiness and sudden loss of muscle tone in patients aged seven or older with a neurological disorder called narcolepsy. (Reporting by Bhanvi Satija and Manojna Maddipatla in Bengaluru; Editing by Devika Syamnath)
